| Generic Name |
Brand Name |
Breast Cancer Subtype |
Breast Cancer Stage |
Where in the drug approval process is this treatment |
| Pertuzumab and Trastuzumab |
PHESGO (pertuzumab and trastuzumab) |
HER2+ |
Stage I, Stage II, Stage III |
Health Canada - Approved, CDA/INNESSS - Public funding review process |
| Pertuzumab and Trastuzumab |
PHESGO (pertuzumab and trastuzumab) |
HER2+ |
Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation |
| Trastuzumab biosimilar |
Ogivri |
HER2+ |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Trazimera |
HER2+ |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Kanjinti |
HER2+ |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Ontruzant |
HER2+ |
Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Herzuma |
HER2+ |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
Health Canada - Approved, PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
HER2+ |
Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
HER2-ultra low |
Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process |
| Trastuzumab deruxtecan |
Enhertu |
HER2-low |
Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
HER2+ |
Stage IV (metastatic) |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
HER2+ |
Stage I, Stage II, Stage III |
Health Canada - Approved, CDA/INNESSS - Public funding review process , PCPA - Provincial & territorial price negotiation, Listed on Provincial/Territorial drug Formulary |
| Trastuzumab Subcutaneous |
Herceptin SC |
HER2+ |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
Health Canada - Approved, PCPA - Provincial & territorial price negotiation |